An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models.

Pochopien, Michal; Paterak, Ewelina; Clay, Emilie; Janik, Justyna; Aballea, Samuel; Biernikiewicz, Malgorzata; Toumi, Mondher

Pochopien, Michal; Paterak, Ewelina; Clay, Emilie; Janik, Justyna; Aballea, Samuel; Biernikiewicz, Malgorzata; Toumi, Mondher.

Afiliação

Pochopien M; Public Health Department, University of Aix-Marseille, Marseille, France.
Paterak E; Modelling, Creativ-Ceutical, Kraków, Poland.
Clay E; Modelling, Creativ-Ceutical, Kraków, Poland.
Janik J; Modelling, Creativ-Ceutical, Paris, France.
Aballea S; Modelling, Creativ-Ceutical, Kraków, Poland.
Biernikiewicz M; Public Health Department, University of Aix-Marseille, Marseille, France.
Toumi M; HEOR, Creativ-Ceutical, Rotterdam, Netherlands.

J Mark Access Health Policy ; 9(1): 2002006, 2021.

Article em En | MEDLINE | ID: mdl-34790341

Palavras-chave

Gene therapy; cost-effectiveness model; economic evaluation; health technology assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation / Health_technology_assessment / Observational_studies / Prognostic_studies Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google